drugset / Trial / NCT05437497

Safety and Efficacy Evaluation of Remimazolam for Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy

NCT05437497

RandomizedParallel-groupTriple-blindSupportive care

Summary

This study aims to compare the safety and efficacy of remimazolam and propofol in EUS-FNA/FNB sedation. This study is a prospective, single-blind study. We plan to enroll 264 patients undergoing EUS-FNA and divide them into two groups. The experimental group was sedated with remimazolam, and the control group was sedated with propofol; safety and efficacy parameters such as intraoperative blood pressure, finger pulse oxygen, heart rate and sedation success rate would be compared. We hypothesized that patients in the experimental group would be superior in terms of safety parameters; the two would be equal in terms of sedation success.

Timeline

Start
2021-08-01
Primary completion
2022-12-31
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 0.5 mg/kg Intravenous
Subject Remimazolam Small molecule 0.05 mg/kg Intravenous

Indications

No indication recorded.